News & Insights

We recently held a webinar featuring presentations from Christoph Birkl (CEO) & Carolyn Hicks (CFO/COO) of portfolio company Brill Power, and Barnaby Balmforth, CEO of portfolio company Biofidelity.

• Oxford Endovascular Ltd is commercialising OxiFlow™, a novel blood flow diversion device (‘stent’) for treating Intracranial Aneurysms (ICAs).
• OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a $10m Series A funding round led by Vulpes Investment Management, a Singapore-based life sciences investor.
• This is the second OTIF investment in Oxford Endovascular to date, bringing total funds invested by the fund in the Company to £500k.

OIC portfolio company Oxehealth has secured financial commitments totalling £10m, which will be delivered in two rounds across 2021 and 2022.

The two rounds have been underwritten by existing shareholders, which included a commitment from the Oxford Technology & Innovations EIS Fund (OTIF) advised by OIC.

OIC investee company SpyBiotech, which is developing a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, has appointed Dan Menichella as an independent, non-executive director and Norman Begg as a scientific advisor.

OIC portfolio company Cytox launches a non-invasive genetic test enabling physicians to assess an individual’s risk of cognitive decline due to Alzheimer’s from a simple saliva sample provided from home.

Excitingly, the test can guide lifestyle interventions to potentially slow disease progression.